OmniAb Announces the Passing of Director Sunil Patel
August 07 2023 - 3:05PM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil
Patel passed away suddenly last week. The Board of Directors and
leadership of OmniAb extend their deepest condolences to those who
loved and cared for Sunil and express their gratitude for Sunil’s
many contributions to OmniAb.
Sunil Patel was appointed to OmniAb’s Board in November 2022
when OmniAb was spun-out of Ligand Pharmaceuticals as an
independent, publicly-traded company, and previously served on the
Ligand Pharmaceuticals Board of Directors since 2010.
“It is with profound sadness that we announce Sunil’s passing,”
said John Higgins, OmniAb Board Chair. “Sunil was a highly-valued
and engaged member of the OmniAb Board of Directors and played an
important role driving our investments and strategy. Above that, he
was a friend and colleague for the past two decades. He will be
remembered by all who had the pleasure of working with him as a
very thoughtful business operator, strongly devoted to cutting-edge
science supporting medical research. He was kind and gentle, and an
independent thinker who brought levity and joy to any meeting or
encounter. Sunil’s support for antibody discovery research and the
formation of OmniAb are among his most important business
contributions. He saw the future of where the field was going and
at every turn helped to drive our strategy. He will be remembered
by those who had the pleasure of knowing him as a warm and
incredibly bright individual of high integrity. For all who knew
Sunil, we will honor his legacy as we advance our work.”
With more than 25 years of senior management and R&D
experience in the biotechnology industry, Mr. Patel most recently
worked as an independent consultant to biotechnology companies
advising on strategy and corporate development initiatives.
Previously, he served in executive roles at OncoMed
Pharmaceuticals, Inc., including Executive Vice President and Chief
Financial Officer. He held senior management positions in corporate
development, marketing and strategy with BiPar Sciences, Inc.,
Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead
Sciences Inc. Early in his career Mr. Patel worked at McKinsey
& Company serving biotechnology and pharmaceutical clients, and
held scientific research positions at ZymoGenetics, Inc. and
ProCyte Corporation. He received an undergraduate degree in
chemistry from the University of California, Berkeley and a
master’s degree in molecular bioengineering/biotechnology from the
University of Washington.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications though a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230807390449/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com Twitter (X)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024